- Conditions
- Platinum Sensitive Ovarian Cancer, Ovarian Cancer
- Interventions
- FRα peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF) Alone
- Biological · Drug
- Lead sponsor
- Marker Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,047
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Tc 99m EC20
- Drug
- Lead sponsor
- Endocyte
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Rheumatoid Arthritis
- Interventions
- SAR153191 (REGN88)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Ocala, Florida • Duncansville, Pennsylvania + 1 more
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Multigated Acquisition Scan, Oxaliplatin
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 207
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 162 more
- Conditions
- Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Interventions
- FOLFIRINOX, Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil (5-FU), NIS793, Chemoradiation, Capecitabine, Radiation Therapy, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- Colin D. Weekes, M.D., PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leukemia
- Interventions
- G-CSF, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, Allopurinol
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2010
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 32 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- OTL38, Intraoperative fluorescence imaging system
- Drug · Device
- Lead sponsor
- Chandru Sundaram
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Stroke, Cerebral Infarction, Myocardial Infarction
- Interventions
- pyridoxine, cyanocobalamin, folic acid multivitamin
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 35 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2004
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Colorectal Cancer
- Interventions
- Bevacizumab, Floxuridine, Irinotecan, Leucovorin
- Biological · Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor, Anaplastic Oligoastrocytoma
- Interventions
- E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium, pharmacological study, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- Regorafenib, 5-Fluorouracil, Leucovorin, Oxaliplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
- Conditions
- Parkinson's Disease
- Interventions
- PD vitamin supplementation, PD exercise intervention, PD vitamin + exercise
- Dietary Supplement · Other
- Lead sponsor
- New York Institute of Technology
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Old Westbury, New York
- Conditions
- Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Cancer Non-Small Cell Stage IIIB, Lung Cancer Non-small Cell Stage IV, Lung Cancer, Non-small Cell
- Interventions
- Luveltamab tazevibulin
- Drug
- Lead sponsor
- Sutro Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- La Jolla, California • Washington D.C., District of Columbia • Lake Mary, Florida + 4 more
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Quality-of-Life Assessment, Questionnaire Administration, Thioguanine, Vincristine Sulfate
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 9,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 213
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
- Conditions
- Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
- Interventions
- bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hepatocellular Cancer
- Interventions
- Leucovorin, Fluorouracil, Oxaliplatin, Sorafenib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Autism Spectrum Disorder
- Interventions
- folinic acid
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 5 Years to 25 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Stroke, Transient Ischemic Attack
- Interventions
- Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo, Placebo
- Drug · Other
- Lead sponsor
- VITATOPS
- Government
- Eligibility
- Not listed
- Enrollment
- 8,164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2009
- U.S. locations
- 4
- States / cities
- New York, New York • Abington, Pennsylvania • Columbia, South Carolina
- Conditions
- Colo-rectal Cancer
- Interventions
- Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine, Leucovorin, Oxaliplatin, Fluorouracil, Bevacizumab, Irinotecan, Cetuximab, Metastasectomy, Biospecimen collection, Computed Tomography, Panitumumbab
- Biological · Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Advanced Solid Tumors
- Interventions
- Calderasib, Pembrolizumab, carboplatin, pemetrexed, cetuximab, oxaliplatin, leucovorin, 5-fluorouracil
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Grand Rapids, Michigan • Hackensack, New Jersey + 3 more
- Conditions
- Pregnancy, Autistic Disorder, Folic Acid Deficiency
- Interventions
- Prenatal supplement
- Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- End Stage Renal Disease, Hyperhomocysteinemia
- Interventions
- cyanocobalamin, folic acid, pyridoxine
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 21 Years to 89 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Multiple Sclerosis
- Interventions
- Progressive exercise, Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV, Modified paleolithic diet, Omega 3 fatty acids, Full Spectrum vitamin, Essential - hydroxytyrosol, Maltodextrin fiber supplement, Mineral boost (magnesium), Niacinamide, Methyl B12, Taurine, creatine, thiamine, riboflavin, N acetylcysteine, alpha lipoic acid, L acetyl carnitine, methyl folate, coenzyme Q, meditation, self massage, learning, Coconut oil
- Other · Device · Dietary Supplement + 1 more
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa